跳至主要内容
临床试验/DRKS00032403
DRKS00032403
招募中
不适用

Deep sensory-vascular profiling of Fabry patients

niversitätsklinikum Schleswig-Holstein, Campus Kiel0 个研究点目标入组 50 人2023年8月8日
适应症Fabry disease

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Fabry disease
发起方
niversitätsklinikum Schleswig-Holstein, Campus Kiel
入组人数
50
状态
招募中
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2023年8月8日
结束日期
待定
最后更新
去年
研究类型
Observational
性别
All

研究者

发起方
niversitätsklinikum Schleswig-Holstein, Campus Kiel

入排标准

入选标准

  • Fabry patients
  • \- patients suffering from chronic pain
  • \- on a stable therapy regimen for at least two years or not receiving treatment
  • \- able to give informed consent
  • healthy controls
  • Chosen according to the criteria provided in: Gierthmühlen J, Enax\-Krumova EK, Attal N, Bouhassira D, Cruccu G, Finnerup NB, Haanpää M, Hansson P, Jensen TS, Freynhagen R, Kennedy JD, Mainka T, Rice ASC, Segerdahl M, Sindrup SH, Serra J, Tölle T, Treede RD, Baron R, Maier C. Who is healthy? Aspects to consider when including healthy volunteers in QST\-\-based studies\-a consensus statement by the EUROPAIN and NEUROPAIN consortia. Pain. 2015 Nov;156(11\):2203\-2211\. doi: 10\.1097/j.pain.0000000000000227\. PMID: 26075963\.

排除标准

  • Fabry patients:
  • \- severe depression
  • \- chronic alcoholism (regular consumption of alcohol exceeding 10 g a day for women and 20 g a day for men) or substance abuse (including consumption of any illegal drugs, consumption of prescription medication (e.g. opioids, benzodiazepines) either not prescribed to the patients or in overly high doses)
  • \- The use of medical cannabis as well as CBD or THC preparation or supplement\-grade CBD (according to German regulations) is permitted. Patients consuming cannabis which is not prescribed by a medical professional and obtained from a pharmacy or licensed dispensary will be excluded.
  • \- patients on investigational drugs
  • \- any reason preventing an accurate understanding of the tests

结局指标

主要结局

未指定

相似试验